Replies to post #382 on ProtoKinetix Inc (PKTX)

[Past and present]

PR NEWS Release..Yes, I know I'm alittle late..PRESS RELEASE >> FEBRUARY 19 - 2009
ProtoKinetix’ AAGP™ is Critical for Stem Cell Therapy

PROTOKINETIX INC. (PKTX: OTCBB)
Vancouver, British Columbia, February 19, 2009
Protokinetix’ (PKTX) results over the last 2-years have clearly shown the vital role that AAGP™ can play in this exciting disease treatment arena. Support for stem cell research has never been stronger and continues to grow. This growth will accelerate as successful results are announced.

One of the most important ingredients for the success of this therapy is the recovery of the maximum number of viable stem cells after storage. These extremely delicate cells typically have a very low yield after cryopreservation. AAGP™ testing that has been conducted on stem cell preservation at all temperatures has shown an impressive increase in survivability and viability.

In summary, over the past 24-months, AAGP™ has demonstrated a remarkable increase in viable cell recovery at temperatures ranging from -196?C (cryopreservation) all the way to 37?C (body temperature). These results have been consistent regardless of the source of the stem cells. As an example, AAGP™ has been independently tested as a protective agent in the cryopreservation (-196?C) and subsequent thawing of umbilical cord blood in low concentrations of AAGP™ (4mg/ml). The resultant analysis revealed a more than double average increase over the control group (cells not protected with AAGP™) in the yield, following thawing.
About ProtoKinetix